China's WuXi PharmaTech, a provider of pharmaceutical R&D outsourcing services, has promoted Mr Edward Hu from Executive Vice President of Operations to Chief Operating Officer (COO).
Mr Hu has joined WuXi PharmaTech in August 2007, prior to that he was a senior vice president and COO of Tanox, later acquired by Genentech. He also worked for Biogen Idec as a business-planning manager and for Merck as a senior financial analyst.
"We are very happy to promote Ed to give him more responsibilities, as Ed has quickly demonstrated his leadership capabilities and ability to contribute to the company. Ed will be based in US to lead the integration of AppTec after the deal is closed," said Dr Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.
Mr Hu received his MBA and MS in Chemistry from Carnegie Mellon University, Pittsburgh, Pennsylvania.